How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-ovarian-hyperstimulation-syndrome.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of ovarian hyperstimulation syndrome — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of ovarian hyperstimulation syndrome (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of ovarian hyperstimulation syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Dostinex	CABERGOLINE	Pfizer Japan Inc.	Ergot Derivative [EPC]	D(2) dopamine receptor		1996-01-01
Dostinex	Dostinex	Par Pharmaceutical, Inc.		D(1B) dopamine receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Par Pharmaceutical, Inc. · 1 drug in Prevention of ovarian hyperstimulation syndrome
Pfizer Japan Inc. · 1 drug in Prevention of ovarian hyperstimulation syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of ovarian hyperstimulation syndrome:

Cite this brief

Drug Landscape (2026). Prevention of ovarian hyperstimulation syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-ovarian-hyperstimulation-syndrome. Accessed 2026-06-10.

Prevention of ovarian hyperstimulation syndrome full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing